Zai Lab Announces First Patient Treated in Mainland China for the Global Phase III FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

Zai Lab, Ltd. announced that the first patient has been treated in the mainland China portion of the global registrational, Phase III FORTITUDE-101 study for bemarituzumab, a potential first-in-class Fc-optimized monoclonal antibody that is designed to block fibroblast growth factors from binding and activating Fibroblast Growth Factor Receptor 2b (FGFR2b), inhibiting several downstream pro-tumor signaling pathways and potentially slowing tumor proliferation.